{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:04Z","timestamp":1787584564840,"version":"build-2736575974"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council"},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["APP1099452"],"award-info":[{"award-number":["APP1099452"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian National Health and Medical Research Council Investigator Grant","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}]},{"name":"NHMRC Investigator Grant","award":["APP1197866"],"award-info":[{"award-number":["APP1197866"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Urosepsis caused by extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the treatment of ESBL infections; however, to minimize the emergence of carbapenem resistance, interest in alternative treatments has heightened.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study compared pharmacodynamics of piperacillin\/tazobactam versus meropenem against ESBL-producing and non-producing E. coli clinical isolates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>E. coli isolates, obtained from national reference laboratory in Bangladesh, were characterized by phenotypic tests, WGS, susceptibility tests and mutant frequency analysis. Three ESBL-producing and two non-producing E. coli were exposed to piperacillin\/tazobactam (4.5\u2005g, every 6\u2005h and every 8\u2005h, 30\u2005min infusion) and meropenem (1\u2005g, every 8\u2005h, 30\u2005min infusion) in a hollow-fibre infection model over 7\u2005days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Piperacillin\/tazobactam regimens attained \u223c4\u20135\u2005log10 cfu\/mL bacterial killing within 24\u2005h and prevented resistance emergence over the experiment against ESBL-producing and non-producing E. coli. However, compared with 8 hourly meropenem, the 6 hourly piperacillin\/tazobactam attained \u223c1\u2005log10 lower bacterial kill against one of three ESBL-producing E. coli (CTAP#173) but comparable killing for the other two ESBL-producing (CTAP#168 and CTAP#169) and two non-producing E. coli (CTAP#179 and CTAP#180). The 6 hourly piperacillin\/tazobactam regimen attained \u223c1\u2005log10 greater bacterial kill compared with the 8 hourly regimen against CTAP#168 and CTAP#179 at 24\u2005h.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study suggests piperacillin\/tazobactam may be a potential alternative to carbapenems to treat urosepsis caused by ESBL-producing E. coli, although clinical trials with robust design are needed to confirm non-inferiority of outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac186","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T17:02:14Z","timestamp":1655744534000},"page":"2448-2455","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacodynamic evaluation of piperacillin\/tazobactam versus meropenem against extended-spectrum \u03b2-lactamase-producing and non-producing <i>Escherichia coli<\/i> clinical isolates in a hollow-fibre infection model"],"prefix":"10.1093","volume":"77","author":[{"given":"Kamrul","family":"Islam","sequence":"first","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade B","family":"Sime","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-9854","authenticated-orcid":false,"given":"Steven C","family":"Wallis","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J","family":"Bauer","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4785","authenticated-orcid":false,"given":"Brian M","family":"Forde","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-0345","authenticated-orcid":false,"given":"Patrick","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmina","family":"Shirin","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakir H","family":"Habib","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meerjady S","family":"Flora","sequence":"additional","affiliation":[{"name":"Directorate General of Health Services, Mohakhali , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane , Australia"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier , N\u00eemes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"2022082518385379100_dkac186-B1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00345-015-1722-1","article-title":"Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013","volume":"34","author":"Tando\u011fdu","year":"2016","journal-title":"World J Urol"},{"key":"2022082518385379100_dkac186-B2","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.UTI-0003-2012","article-title":"Urosepsis: overview of the diagnostic and treatment challenges","volume":"3","author":"Wagenlehner","year":"2015","journal-title":"Microbiol Spectr"},{"key":"2022082518385379100_dkac186-B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/ijccm.IJCCM_322_17","article-title":"Outcome of patients admitted to a tertiary referral intensive care unit with urosepsis needing source control","volume":"22","author":"Rao","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"2022082518385379100_dkac186-B4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1473-3099(12)70239-6","article-title":"Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study","volume":"12","author":"Levy","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022082518385379100_dkac186-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00345-019-02963-9","article-title":"Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study","volume":"38","author":"Tandogdu","year":"2020","journal-title":"World J Urol"},{"key":"2022082518385379100_dkac186-B6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2022082518385379100_dkac186-B7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2022082518385379100_dkac186-B8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"2022082518385379100_dkac186-B9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14756366.2017.1344235","article-title":"\u03b2-lactamase database (BLDB)\u2013structure and function","volume":"32","author":"Naas","year":"2017","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2022082518385379100_dkac186-B10","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/jac\/dkx146","article-title":"Global epidemiology of CTX-M \u03b2-lactamases: temporal and geographical shifts in genotype","volume":"72","author":"Bevan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022082518385379100_dkac186-B11","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/jac\/dkab269","article-title":"ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18","volume":"76","author":"Karlowsky","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082518385379100_dkac186-B12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2217\/fmb-2020-0193","article-title":"Epidemiology of extended-spectrum \u03b2-lactamase and metallo-\u03b2-lactamase-producing Escherichia coli in South Asia","volume":"16","author":"Islam","year":"2021","journal-title":"Future Microbiol"},{"key":"2022082518385379100_dkac186-B13","doi-asserted-by":"crossref","first-page":"663033","DOI":"10.3389\/fmicb.2021.663033","article-title":"High prevalence of extended-spectrum \u03b2-lactamases in Escherichia coli strains collected from strictly defined community-acquired urinary tract infections in adults in China: A multicenter prospective clinical microbiological and molecular study","volume":"12","author":"Jia","year":"2021","journal-title":"Front Microbiol"},{"key":"2022082518385379100_dkac186-B14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jiph.2020.01.004","article-title":"Antimicrobial resistance of Gram-negative bacteria: A six-year longitudinal study in a hospital in Saudi Arabia","volume":"13","author":"Al-Tawfiq","year":"2020","journal-title":"J Infect Public Health"},{"key":"2022082518385379100_dkac186-B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhin.2015.10.001","article-title":"Impact of infection with extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs","volume":"92","author":"Maslikowska","year":"2016","journal-title":"J Hosp Infect"},{"key":"2022082518385379100_dkac186-B16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1128\/AAC.50.4.1257-1262.2006","article-title":"Clinical and economic impact of bacteremia with extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"50","author":"Schwaber","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B17","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022082518385379100_dkac186-B18","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B19","first-page":"Dc08","article-title":"Relationship between Antimicrobial Consumption and the Incidence of Antimicrobial Resistance in Escherichia coli and Klebsiella pneumoniae Isolates","volume":"9","author":"Joseph","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"2022082518385379100_dkac186-B20","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"2022082518385379100_dkac186-B21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of \u03b2-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2022082518385379100_dkac186-B22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 \u03b2-lactamase and non-susceptibility to penicillin\/\u03b2-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518385379100_dkac186-B23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam versus meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2022082518385379100_dkac186-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2022082518385379100_dkac186-B25","author":"Institute of Epidemiology, Disease Control and Research","year":"2018"},{"key":"2022082518385379100_dkac186-B26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat Protoc"},{"key":"2022082518385379100_dkac186-B27","author":"EUCAST","year":"2021"},{"key":"2022082518385379100_dkac186-B28","doi-asserted-by":"crossref","first-page":"e01763-16","DOI":"10.1128\/AAC.01763-16","article-title":"Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy","volume":"61","author":"Sime","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B29","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1093\/jac\/dkw153","article-title":"Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling","volume":"71","author":"Bergen","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022082518385379100_dkac186-B30","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022082518385379100_dkac186-B31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2022082518385379100_dkac186-B32","doi-asserted-by":"crossref","first-page":"e01276-16","DOI":"10.1128\/AAC.01276-16","article-title":"Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients","volume":"61","author":"Alobaid","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","article-title":"Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients","volume":"72","author":"Mattioli","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2022082518385379100_dkac186-B34","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine"},{"key":"2022082518385379100_dkac186-B35","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/cid\/ciz1205","article-title":"Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing organisms?","volume":"71","author":"Sharara","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022082518385379100_dkac186-B36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2019.05.013","article-title":"Urinary piperacillin\/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae","volume":"54","author":"Gould","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2022082518385379100_dkac186-B37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/9781119772767.ch10","volume-title":"Drug Delivery Approaches","author":"Sime","year":"2021"},{"key":"2022082518385379100_dkac186-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2022082518385379100_dkac186-B39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/1120009X.2016.1140858","article-title":"Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa","volume":"28","author":"Zelenitsky","year":"2016","journal-title":"J Chemother"},{"key":"2022082518385379100_dkac186-B40","author":"EMA","year":"2016"},{"key":"2022082518385379100_dkac186-B41","author":"FDA"},{"key":"2022082518385379100_dkac186-B42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/infdis\/jiu237","article-title":"Interaction of drug-and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model","volume":"210","author":"Drusano","year":"2014","journal-title":"J Infect Dis"},{"key":"2022082518385379100_dkac186-B43","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","article-title":"Kinetic interactions of tazobactam with \u03b2-lactamases from all major structural classes","volume":"37","author":"Bush","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518385379100_dkac186-B45","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, \u03b2-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022082518385379100_dkac186-B46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/CMR.1.1.109","article-title":"\u03b2-lactamase inhibitors from laboratory to clinic","volume":"1","author":"Bush","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"2022082518385379100_dkac186-B47","first-page":"187","article-title":"Outcomes analysis in patients with extended-spectrum \u03b2-lactamase bacteremia empirically treated with piperacillin\/tazobactam versus carbapenems","volume":"32","author":"John","year":"2019","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2022082518385379100_dkac186-B48","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022082518385379100_dkac186-B49","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2448\/45536614\/dkac186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2448\/45536614\/dkac186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T18:41:43Z","timestamp":1661452903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/9\/2448\/6611847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,20]]},"published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac186","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,20]]}}}